Benzinga
Published Nov 01, 2023 16:00
Updated Nov 01, 2023 17:10
Analyzing DexCom In Comparison To Competitors In Health Care Equipment & Supplies Industry
Benzinga - by Benzinga Insights, Benzinga Staff Writer.
In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating DexCom (NASDAQ:DXCM) in relation to its major competitors in the Health Care Equipment & Supplies industry. By closely examining key financial metrics, market standing, and growth prospects, our objective is to provide valuable insights and highlight company's performance in the industry.
DexCom Background Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
DexCom Inc | 97.62 | 15.13 | 11.17 | 5.53% | $0.29 | $0.62 | 26.69% |
Stryker Corp | 38.17 | 5.91 | 5.32 | 4.31% | $1.23 | $3.18 | 11.2% |
Medtronic PLC | 26.04 | 1.83 | 2.98 | 1.54% | $2.02 | $5.07 | 4.49% |
Becton Dickinson & Co | 45.71 | 2.83 | 3.80 | 1.52% | $1.16 | $2.1 | 5.11% |
Edwards Lifesciences Corp | 27.23 | 5.80 | 6.70 | 5.91% | $0.46 | $1.13 | 12.27% |
IDEXX Laboratories Inc | 42.35 | 30.31 | 9.54 | 23.18% | $0.32 | $0.57 | 9.65% |
GE HealthCare Technologies Inc | 18.43 | 4.26 | 1.59 | 6.06% | $0.86 | $1.94 | 7.43% |
Zimmer Biomet Holdings Inc | 43.50 | 1.76 | 3.05 | 1.71% | $0.57 | $1.34 | 4.93% |
ResMed Inc | 22.96 | 4.89 | 4.76 | 5.24% | $0.34 | $0.6 | 16.0% |
Steris PLC | 173.54 | 3.36 | 4.12 | 2.02% | $0.33 | $0.57 | 11.07% |
Hologic Inc | 33.93 | 3.13 | 4.10 | -0.77% | $0.12 | $0.37 | -1.83% |
Insulet Corp | 147.19 | 16.70 | 6.36 | 5.17% | $0.06 | $0.26 | 32.43% |
Teleflex Inc | 23.69 | 2.06 | 3.01 | 2.67% | $0.21 | $0.41 | 5.5% |
ShockWave Medical Inc | 32.15 | 12.29 | 12.75 | 4.86% | $0.04 | $0.16 | 49.21% |
Penumbra Inc | 254.87 | 6.89 | 7.86 | 1.81% | $0.02 | $0.17 | 25.51% |
Masimo Corp | 38.09 | 3.28 | 2.01 | 1.19% | $0.06 | $0.22 | -19.46% |
Envista Holdings Corp | 18.77 | 0.88 | 1.59 | 1.21% | $0.13 | $0.38 | 2.57% |
Average | 61.66 | 6.64 | 4.97 | 4.23% | $0.5 | $1.15 | 11.0% |
th, td { padding: 8px; text-align: left; }
th { background-color: #293a5a; color: #fff; text-align: left; }
tr:nth-child(even) { background-color: #f2f4f8; }
tr:hover { background-color: #e1e4ea; }
td:nth-child(3), td:nth-child(5) { text-align: left; }
.dividend-amount { font-weight: bold; color: #0d6efd; }
.dividend-frequency { font-size: 12px; color: #6c757d; } After examining DexCom, the following trends can be inferred:
The debt-to-equity (D/E) ratio helps evaluate the capital structure and financial leverage of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In light of the Debt-to-Equity ratio, a comparison between DexCom and its top 4 peers reveals the following information:
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.